AbCellera Biologics (ABCL) Competitors $2.76 -0.16 (-5.48%) (As of 11/14/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends ABCL vs. FOLD, VRNA, HCM, ZLAB, DYN, AGIO, MOR, CPRX, GMTX, and JANXShould you be buying AbCellera Biologics stock or one of its competitors? The main competitors of AbCellera Biologics include Amicus Therapeutics (FOLD), Verona Pharma (VRNA), HUTCHMED (HCM), Zai Lab (ZLAB), Dyne Therapeutics (DYN), Agios Pharmaceuticals (AGIO), MorphoSys (MOR), Catalyst Pharmaceuticals (CPRX), Gemini Therapeutics (GMTX), and Janux Therapeutics (JANX). These companies are all part of the "pharmaceutical preparations" industry. AbCellera Biologics vs. Amicus Therapeutics Verona Pharma HUTCHMED Zai Lab Dyne Therapeutics Agios Pharmaceuticals MorphoSys Catalyst Pharmaceuticals Gemini Therapeutics Janux Therapeutics Amicus Therapeutics (NASDAQ:FOLD) and AbCellera Biologics (NASDAQ:ABCL) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, valuation, risk, earnings, profitability, institutional ownership, analyst recommendations and community ranking. Do analysts prefer FOLD or ABCL? Amicus Therapeutics presently has a consensus price target of $17.63, suggesting a potential upside of 72.62%. AbCellera Biologics has a consensus price target of $8.67, suggesting a potential upside of 201.97%. Given AbCellera Biologics' higher probable upside, analysts plainly believe AbCellera Biologics is more favorable than Amicus Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amicus Therapeutics 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.89AbCellera Biologics 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Which has better valuation & earnings, FOLD or ABCL? AbCellera Biologics has lower revenue, but higher earnings than Amicus Therapeutics. Amicus Therapeutics is trading at a lower price-to-earnings ratio than AbCellera Biologics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAmicus Therapeutics$399.36M7.64-$151.58M-$0.34-30.03AbCellera Biologics$38.03M22.29-$146.40M-$0.61-4.70 Is FOLD or ABCL more profitable? Amicus Therapeutics has a net margin of -21.21% compared to AbCellera Biologics' net margin of -533.32%. AbCellera Biologics' return on equity of -15.73% beat Amicus Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Amicus Therapeutics-21.21% -15.97% -3.17% AbCellera Biologics -533.32%-15.73%-12.22% Which has more risk & volatility, FOLD or ABCL? Amicus Therapeutics has a beta of 0.68, suggesting that its stock price is 32% less volatile than the S&P 500. Comparatively, AbCellera Biologics has a beta of 0.35, suggesting that its stock price is 65% less volatile than the S&P 500. Does the media prefer FOLD or ABCL? In the previous week, Amicus Therapeutics had 3 more articles in the media than AbCellera Biologics. MarketBeat recorded 19 mentions for Amicus Therapeutics and 16 mentions for AbCellera Biologics. Amicus Therapeutics' average media sentiment score of 0.56 beat AbCellera Biologics' score of 0.00 indicating that Amicus Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amicus Therapeutics 5 Very Positive mention(s) 4 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive AbCellera Biologics 2 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals & insiders hold more shares of FOLD or ABCL? 61.4% of AbCellera Biologics shares are held by institutional investors. 2.2% of Amicus Therapeutics shares are held by insiders. Comparatively, 28.0% of AbCellera Biologics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Does the MarketBeat Community favor FOLD or ABCL? Amicus Therapeutics received 474 more outperform votes than AbCellera Biologics when rated by MarketBeat users. However, 75.71% of users gave AbCellera Biologics an outperform vote while only 73.40% of users gave Amicus Therapeutics an outperform vote. CompanyUnderperformOutperformAmicus TherapeuticsOutperform Votes52773.40% Underperform Votes19126.60% AbCellera BiologicsOutperform Votes5375.71% Underperform Votes1724.29% SummaryAmicus Therapeutics beats AbCellera Biologics on 10 of the 18 factors compared between the two stocks. Ad Porter & CompanyThe next assassination attempt won’t be on TrumpPresident Trump is soon to be back in the White House. Unity has been restored to the U.S. But if you watched the President’s 25-minute victory speech, you probably noticed he spent nearly four minutes speaking about one very controversial person.I share with you in this special investigative documentary. Get AbCellera Biologics News Delivered to You Automatically Sign up to receive the latest news and ratings for ABCL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ABCL vs. The Competition Export to ExcelMetricAbCellera BiologicsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$847.71M$7.11B$5.33B$8.91BDividend YieldN/A8.03%4.98%4.03%P/E Ratio-4.7011.25135.4417.46Price / Sales22.29393.051,266.8895.47Price / CashN/A49.2238.8936.42Price / Book0.799.126.315.92Net Income-$146.40M$153.75M$118.33M$224.86M7 Day Performance5.51%-1.20%-1.43%-0.38%1 Month Performance13.89%8.48%3.12%4.21%1 Year Performance-33.72%39.61%36.57%27.31% AbCellera Biologics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ABCLAbCellera Biologics2.971 of 5 stars$2.76-5.5%$8.67+214.0%-26.6%$815.21M$32.96M-4.52586FOLDAmicus Therapeutics4.6224 of 5 stars$10.99+0.1%N/A+1.0%$3.26B$399.36M-32.32480Analyst ForecastShort Interest ↓VRNAVerona Pharma2.4178 of 5 stars$38.58+1.0%N/A+159.3%$3.13B$460,000.00-20.0930HCMHUTCHMED1.717 of 5 stars$17.95-4.0%N/A-8.0%$3.13B$420.26M0.001,988Short Interest ↓Gap DownZLABZai Lab3.1408 of 5 stars$30.62-0.6%N/A+10.8%$3.05B$266.72M-10.012,175News CoverageGap DownDYNDyne Therapeutics3.641 of 5 stars$28.48-2.7%N/A+292.3%$2.99BN/A-7.93100Earnings ReportAnalyst ForecastShort Interest ↑News CoverageGap DownAGIOAgios Pharmaceuticals3.3437 of 5 stars$59.06+7.2%N/A+174.6%$2.94B$26.82M5.20390Short Interest ↑High Trading VolumeMORMorphoSys0.0778 of 5 stars$18.96flatN/AN/A$2.86B$238.28M-5.45730CPRXCatalyst Pharmaceuticals4.8288 of 5 stars$23.93+2.9%N/A+80.5%$2.85B$460.48M20.28167Analyst ForecastHigh Trading VolumeGMTXGemini TherapeuticsN/A$65.00+2.6%N/A+30.2%$2.82BN/A-65.0030Gap DownHigh Trading VolumeJANXJanux Therapeutics3.6165 of 5 stars$53.92-0.5%N/A+633.3%$2.81B$8.08M-46.0930Analyst Revision Related Companies and Tools Related Companies Amicus Therapeutics Competitors Verona Pharma Competitors HUTCHMED Competitors Zai Lab Competitors Dyne Therapeutics Competitors Agios Pharmaceuticals Competitors MorphoSys Competitors Catalyst Pharmaceuticals Competitors Gemini Therapeutics Competitors Janux Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ABCL) was last updated on 11/14/2024 by MarketBeat.com Staff From Our PartnersBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredTrump won. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will ...Weiss Ratings | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredElon Musk’s $30 Billion Trump Bet Pays Off—What’s Next?Elon Musk bet big on Trump's victory, and that gamble has already added over $30 billion to his net worth in a...InvestorPlace | SponsoredNew post-election stock warning from Wall StreetIf you’re holding U.S. stocks, it may be time to brace for impact. The S&P 500 crossed 6,000 for the first ...Chaikin Analytics | SponsoredBreaking News: Are Trump/Musk Planning an AI Takeover? (Shocking)Now that he is Donald Trump’s right-hand man… You owe it to yourself to see Elon Musk’s big AI prediction f...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AbCellera Biologics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AbCellera Biologics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ABCL Stock Alerts